918 results on '"Bono, F."'
Search Results
2. Economic assessment of NGS testing workflow for NSCLC in a healthcare setting
- Author
-
Seminati, D, L'Imperio, V, Casati, G, Ceku, J, Pilla, D, Scalia, C, Gragnano, G, Pepe, F, Pisapia, P, Sala, L, Cortinovis, D, Bono, F, Malapelle, U, Troncone, G, Novello, S, Pagni, F, Seminati, Davide, L'Imperio, Vincenzo, Casati, Gabriele, Ceku, Joranda, Pilla, Daniela, Scalia, Carla Rossana, Gragnano, Gianluca, Pepe, Francesco, Pisapia, Pasquale, Sala, Luca, Cortinovis, Diego Luigi, Bono, Francesca, Malapelle, Umberto, Troncone, Giancarlo, Novello, Silvia, Pagni, Fabio, Seminati, D, L'Imperio, V, Casati, G, Ceku, J, Pilla, D, Scalia, C, Gragnano, G, Pepe, F, Pisapia, P, Sala, L, Cortinovis, D, Bono, F, Malapelle, U, Troncone, G, Novello, S, Pagni, F, Seminati, Davide, L'Imperio, Vincenzo, Casati, Gabriele, Ceku, Joranda, Pilla, Daniela, Scalia, Carla Rossana, Gragnano, Gianluca, Pepe, Francesco, Pisapia, Pasquale, Sala, Luca, Cortinovis, Diego Luigi, Bono, Francesca, Malapelle, Umberto, Troncone, Giancarlo, Novello, Silvia, and Pagni, Fabio
- Abstract
Background: The molecular diagnostic and therapeutic pathway of Non-Small Cell Lung Cancer (NSCLC) stands as a successful example of precision medicine. The scarcity of material and the increasing number of biomarkers to be tested have prompted the routine application of next-generation-sequencing (NGS) techniques. Despite its undeniable advantages, NGS involves high costs that may impede its broad adoption in laboratories. This study aims to assess the detailed costs linked to the integration of NGS diagnostics in NSCLC to comprehend their financial impact. Materials and methods: The retrospective analysis encompasses 210 cases of early and advanced stages NSCLC, analyzed with NGS and collected at the IRCCS San Gerardo dei Tintori Foundation (Monza, Italy). Molecular analyses were conducted on FFPE samples, with an hotspot panel capable of detecting DNA and RNA variants in 50 clinically relevant genes. The economic analysis employed a full-cost approach, encompassing direct and indirect costs, overheads, VAT (Value Added Tax). Results: We estimate a comprehensive cost for each sample of €1048.32. This cost represents a crucial investment in terms of NSCLC patients survival, despite constituting only around 1% of the expenses incurred in their molecular diagnostic and therapeutic pathway. Conclusions: The cost comparison between NGS test and the notably higher therapeutic costs highlights that the diagnostic phase is not the limiting economic factor. Developing NGS facilities structured in pathology networks may ensure appropriate technical expertise and efficient workflows.
- Published
- 2024
3. Digital counting of tissue cells for molecular analysis: the QuANTUM pipeline
- Author
-
L’Imperio, V, Cazzaniga, G, Mannino, M, Seminati, D, Mascadri, F, Ceku, J, Casati, G, Bono, F, Eloy, C, Rocco, E, Frascarelli, C, Fassan, M, Malapelle, U, Pagni, F, L’Imperio, Vincenzo, Cazzaniga, Giorgio, Mannino, Mauro, Seminati, Davide, Mascadri, Francesco, Ceku, Joranda, Casati, Gabriele, Bono, Francesca, Eloy, Catarina, Rocco, Elena Guerini, Frascarelli, Chiara, Fassan, Matteo, Malapelle, Umberto, Pagni, Fabio, L’Imperio, V, Cazzaniga, G, Mannino, M, Seminati, D, Mascadri, F, Ceku, J, Casati, G, Bono, F, Eloy, C, Rocco, E, Frascarelli, C, Fassan, M, Malapelle, U, Pagni, F, L’Imperio, Vincenzo, Cazzaniga, Giorgio, Mannino, Mauro, Seminati, Davide, Mascadri, Francesco, Ceku, Joranda, Casati, Gabriele, Bono, Francesca, Eloy, Catarina, Rocco, Elena Guerini, Frascarelli, Chiara, Fassan, Matteo, Malapelle, Umberto, and Pagni, Fabio
- Abstract
The estimation of tumor cellular fraction (TCF) is a crucial step in predictive molecular pathology, representing an entry adequacy criterion also in the next-generation sequencing (NGS) era. However, heterogeneity of quantification practices and inter-pathologist variability hamper the robustness of its evaluation, stressing the need for more reliable results. Here, 121 routine histological samples from non-small cell lung cancer (NSCLC) cases with complete NGS profiling were used to evaluate TCF interobserver variability among three different pathologists (pTCF), developing a computational tool (cTCF) and assessing its reliability vs ground truth (GT) tumor cellularity and potential impact on the final molecular results. Inter-pathologist reproducibility was fair to good, with overall Wk ranging between 0.46 and 0.83 (avg. 0.59). The obtained cTCF was comparable to the GT (p = 0.129, 0.502, and 0.130 for surgical, biopsies, and cell block, respectively) and demonstrated good reliability if elaborated by different pathologists (Wk = 0.9). Overall cTCF was lower as compared to pTCF (30 ± 10 vs 52 ± 19, p < 0.001), with more cases < 20% (17, 14%, p = 0.690), but none containing < 100 cells for the algorithm. Similarities were noted between tumor area estimation and pTCF (36 ± 29, p < 0.001), partly explaining variability in the human assessment of tumor cellularity. Finally, the cTCF allowed a reduction of the copy number variations (CNVs) called (27 vs 29, − 6.9%) with an increase of effective CNVs detection (13 vs 7, + 85.7%), some with potential clinical impact previously undetected with pTCF. An automated computational pipeline (Qupath Analysis of Nuclei from Tumor to Uniform Molecular tests, QuANTUM) has been created and is freely available as a QuPath extension. The computational method used in this study has the potential to improve efficacy and reliability of TCF estimation in NSCLC, with demonstrated impact on the final molecular results.
- Published
- 2024
4. State of play and challenges for the successful implementation of indirect structural health monitoring (iSHM) for bridges
- Author
-
Gkoumas, K., primary, Bono, F., additional, Galassi, M.C., additional, Gkoktsi, K., additional, and Tirelli, D., additional
- Published
- 2021
- Full Text
- View/download PDF
5. The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases
- Author
-
Luppi, F, Manfredi, A, Faverio, P, Andersen, M, Bono, F, Pagni, F, Salvarani, C, Bendstrup, E, Sebastiani, M, Luppi F., Manfredi A., Faverio P., Andersen M. B., Bono F., Pagni F., Salvarani C., Bendstrup E., Sebastiani M., Luppi, F, Manfredi, A, Faverio, P, Andersen, M, Bono, F, Pagni, F, Salvarani, C, Bendstrup, E, Sebastiani, M, Luppi F., Manfredi A., Faverio P., Andersen M. B., Bono F., Pagni F., Salvarani C., Bendstrup E., and Sebastiani M.
- Abstract
Usual Interstitial Pneumonia (UIP) is characterized by progression of lung parenchyma that may be observed in various autoimmune rheumatic diseases (ARDs), including rheumatoid arthritis and connective tissue diseases. From a diagnostic point of view, a UIP pattern related to ARDs may display imaging and pathological features able to distinguish it from that related to IPF, such as the "straight-edge" sign at HRCT and lymphoplasmacytic infiltrates at histologic specimens. Multidisciplinary approach (MDD), involving at least pulmonologist, rheumatologist and radiologist, is fundamental in the differential diagnosis process, but MDD is also required in the evaluation of severity, progression and response to treatment, that is based on the combination of changes in symptoms, pulmonary function trends, and, in selected patients, serial CT evaluation. Differently from IPF, in patients with ARDs both functional evaluation and patient-reported outcomes may be affected by systemic involvement and comorbidities, including musculoskeletal manifestations of disease. Finally, in regards to pharmacological treatment, immunosuppressants have been considered the cornerstone of therapy, despite the lack of solid evidence in most cases; recently, antifibrotic drugs were also proposed for the treatment of progressive fibrosing ILDs other than IPF. In ARD-ILD, the therapeutic choice should balance the need for the control of systemic and lung involvements with the risk of adverse events from multi-morbidities and -therapies. Purpose of this review is to summarize the definition, the radiological and morphological features of the UIP pattern in ARDs, together with risk factors, diagnostic criteria, prognostic evaluation, monitoring and management approaches of the UIP-ARDs.
- Published
- 2023
6. A Novel Tool for the Early Identification of Frailty in Elderly People: The Application in Primary Care Settings
- Author
-
Maggio, Marcello, Barbolini, M., Longobucco, Y., Barbieri, L., Benedetti, C., Bono, F., Cacciapuoti, I., Donatini, A., Iezzi, E., Papini, D., Rodelli, P. M., Tagliaferri, S., and Moro, M. L.
- Published
- 2020
- Full Text
- View/download PDF
7. Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold
- Author
-
Orlandi, R, Bono, F, Cortinovis, D, Cardillo, G, Cioffi, U, Guttadauro, A, Pirondini, E, Canova, S, Cassina, E, Raveglia, F, Orlandi R., Bono F., Cortinovis D. L., Cardillo G., Cioffi U., Guttadauro A., Pirondini E., Canova S., Cassina E. M., Raveglia F., Orlandi, R, Bono, F, Cortinovis, D, Cardillo, G, Cioffi, U, Guttadauro, A, Pirondini, E, Canova, S, Cassina, E, Raveglia, F, Orlandi R., Bono F., Cortinovis D. L., Cardillo G., Cioffi U., Guttadauro A., Pirondini E., Canova S., Cassina E. M., and Raveglia F.
- Abstract
Malignant Pleural Mesothelioma (MPM) is a highly aggressive disease whose diagnosis could be challenging and confusing. It could occur with atypical presentations on every examined level. Here, we present three unconventional cases of the complex diagnostic process of MPM that we have experienced during routine practice: a patient with reactive mesothelial hyperplasia mimicking MPM, an unexpected presentation of MPM with persistent unilateral hydropneumothorax, a rare case of MPM in situ. Then, we review the relevant literature on each of these topics. Definitive biomarkers to confidently distinguish MPM from other pleural affections are still demanded. Patients presenting with persistent hydropneumothorax must always be investigated for MPM. MPM in situ is now a reality, and this raises questions about its management.
- Published
- 2022
8. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
- Author
-
Canova, S, Ceresoli, G, Grosso, F, Zucali, P, Gelsomino, F, Pasello, G, Mencoboni, M, Rulli, E, Galli, F, De Simone, I, Carlucci, L, De Angelis, A, Belletti, M, Bonomi, M, D'Aveni, A, Perrino, M, Bono, F, Cortinovis, D, Colonese, F, Abbate, M, Sala, L, Sala, E, Perez Gila, M, Pagni, F, Ugo, F, De Vincenzo, F, Santoro, A, Ardizzoni, A, Frega, S, D'Incalci, M, Poli, D, Torri, V, Canova S., Ceresoli G. L., Grosso F., Zucali P. A., Gelsomino F., Pasello G., Mencoboni M., Rulli E., Galli F., De Simone I., Carlucci L., De Angelis A., Belletti M., Bonomi M., D'Aveni A., Perrino M., Bono F., Cortinovis D. L., Cortinovis D., Colonese F., Abbate M. I., Sala L., Sala E., Perez Gila M., Pagni F., Ugo F., De Vincenzo F., Santoro A., Ardizzoni A., Frega S., D'Incalci M., Poli D., Torri V., Canova, S, Ceresoli, G, Grosso, F, Zucali, P, Gelsomino, F, Pasello, G, Mencoboni, M, Rulli, E, Galli, F, De Simone, I, Carlucci, L, De Angelis, A, Belletti, M, Bonomi, M, D'Aveni, A, Perrino, M, Bono, F, Cortinovis, D, Colonese, F, Abbate, M, Sala, L, Sala, E, Perez Gila, M, Pagni, F, Ugo, F, De Vincenzo, F, Santoro, A, Ardizzoni, A, Frega, S, D'Incalci, M, Poli, D, Torri, V, Canova S., Ceresoli G. L., Grosso F., Zucali P. A., Gelsomino F., Pasello G., Mencoboni M., Rulli E., Galli F., De Simone I., Carlucci L., De Angelis A., Belletti M., Bonomi M., D'Aveni A., Perrino M., Bono F., Cortinovis D. L., Cortinovis D., Colonese F., Abbate M. I., Sala L., Sala E., Perez Gila M., Pagni F., Ugo F., De Vincenzo F., Santoro A., Ardizzoni A., Frega S., D'Incalci M., Poli D., and Torri V.
- Abstract
Background: Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate and few therapeutic options. After platinum–pemetrexed combination, no further promising drug seems to be effective. Immune checkpoint inhibitors may have some activity in pretreated patients and no data are available in this population about durvalumab. Materials and methods: DIADEM was a multicenter, open-label, single-arm, phase II trial aimed at evaluating the efficacy and safety of durvalumab. Patients with locally advanced/metastatic MPM who progressed after platinum–pemetrexed chemotherapy were enrolled to receive durvalumab (1500 mg, intravenously Q4W) for 12 months or until evidence of disease progression or unacceptable toxicity. The primary endpoint was the proportion of patients alive and free from progression at 16 weeks (PFS16wks) calculated from treatment initiation. Secondary endpoints were progression-free survival, overall survival, overall response rate, and safety. Results: Sixty-nine patients with a median age of 69 years (range 44-82 years) were enrolled; 62 patients (89.9%) had epithelioid histotype. As first-line treatment, all patients received platinum derivatives–pemetrexed combination (60.9% with carboplatin and 39.1% with cisplatin). As of March 2021, the median follow-up was 9.2 months (interquartile range 5.2-11.1 months). Six patients (8.7%) completed the 12-month treatment; 60 patients discontinued, of whom 42 for progressive disease, and 4 died. Seventeen patients (28.3%; 95% confidence interval 17.5% to 41.4%) were alive or free from progression at 16 weeks. Eleven patients (18.6%) had a grade 3 or 4 treatment-related adverse event (AE), and one (1.4%) had a grade ≥3 immune-related, treatment-related AE. There was one drug-related death. Conclusion: Durvalumab alone in pretreated non-selected MPM did not reach a meaningful clinical activity, showing any new major safety issue signals.
- Published
- 2022
9. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
- Author
-
Rossi G, Jocollé G, Conti A, Tiseo M, Zito Marino F, Donati G, Franco R, Bono F, Barbisan F, and Facchinetti F
- Subjects
lung ,adenocarcinoma ,ROS1 ,FISH ,immunohistochemistry ,NGS ,rearrangement ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Giulio Rossi,1 Genny Jocollé,2 Antonia Conti,3 Marcello Tiseo,4 Federica Zito Marino,5,6 Giovanni Donati,7 Renato Franco,5,6 Francesca Bono,8 Francesca Barbisan,9 Francesco Facchinetti4,10 1Pathology Unit, 2Oncology Unit, Azienda USL Valle d’Aosta, Regional Hospital “Parini”, Aosta, 3Medical Illustrator, Riccione, 4Medical Oncology Unit, University Hospital of Parma, Parma, 5Pathology Unit, Istituto Nazionale Tumori Fondazione G. Pascale, 6Pathology Unit, Luigi Vanvitelli University of Campania, Naples, 7Unit of Thoracic and Senology Surgery, Azienda USL Valle d’Aosta, Regional Hospital “Parini”, Aosta, 8Unit of Pathologic Anatomy, San Gerardo Hospital, IRCCS, Monza, 9Pathology Unit, University Hospital, Azienda Ospedali Riuniti, Ancona, Italy; 10INSERM, U981, Gustave Roussy Cancer Campus, Villejuif, France Abstract: ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer and is associated with slight/never smoking patients and adenocarcinoma histology. Identification of ROS1 rearrangement is mandatory to permit targeted therapy with specific inhibitors, demonstrating a significantly better survival when compared with conventional chemotherapy. Detection of ROS1 rearrangement is based on in situ (immunohistochemistry, fluorescence in situ hybridization) and extractive non-in situ assays. While fluorescence in situ hybridization still represents the gold standard in clinical trials, this technique may fail to recognize rearrangements of ROS1 with some gene fusion partner. On the other hand, immunohistochemistry is the most cost-effective screening technique, but it seems to be characterized by low specificity. Extractive molecular assays are expensive and laborious methods, but they specifically recognize almost all ROS1 fusions using a limited amount of mRNA even from formalin-fixed, paraffin-embedded tumor tissues. This review is a discussion on the present and futuristic diagnostic scenario of ROS1 identification in lung cancer. Keywords: lung, adenocarcinoma, ROS1, FISH, immunohistochemistry, NGS, rearrangement
- Published
- 2017
10. Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- Author
-
Barbanti P., Aurilia C., Cevoli S., Egeo G., Fofi L., Messina R., Salerno A., Torelli P., Albanese M., Carnevale A., Bono F., D'Amico D., Filippi M., Altamura C., Vernieri F., Colombo B., Frediani F., Mercuri B., D'Onofrio F., Grazzi L., Aguggia M., Pierangeli G., Favoni V., Finocchi C., Di Fiore P., Costa C. M., Brunelli N., Fallacara A., Bertuzzo D., Zucco M., Di Clemente L., Trimboli M., Pascarella A., Manzo L., Barbanti P., Aurilia C., Cevoli S., Egeo G., Fofi L., Messina R., Salerno A., Torelli P., Albanese M., Carnevale A., Bono F., D'Amico D., Filippi M., Altamura C., Vernieri F., Colombo B., Frediani F., Mercuri B., D'Onofrio F., Grazzi L., Aguggia M., Pierangeli G., Favoni V., Finocchi C., Di Fiore P., Costa C.M., Brunelli N., Fallacara A., Bertuzzo D., Zucco M., Di Clemente L., Trimboli M., Pascarella A., Manzo L., Barbanti, Piero, Aurilia, Cinzia, Cevoli, Sabina, Egeo, Gabriella, Fofi, Luisa, Messina, Roberta, Salerno, Antonio, Torelli, Paola, Albanese, Maria, Carnevale, Antonio, Bono, Francesco, D'Amico, Domenico, Filippi, Massimo, Altamura, Claudia, and Vernieri, Fabrizio
- Subjects
Adult ,Male ,Calcitonin Gene-Related Peptide Receptor Antagonist ,medicine.medical_specialty ,Visual analogue scale ,Migraine Disorders ,Population ,Analgesic ,Longitudinal Studie ,Sex Factor ,Calcitonin gene-related peptide ,Antibodies, Monoclonal, Humanized ,calcitonin gene-related peptide ,Sex Factors ,Chronic Migraine ,Migraine Disorder ,Calcitonin Gene-Related Peptide Receptor Antagonists ,Interquartile range ,Internal medicine ,Outcome Assessment, Health Care ,sex ,Humans ,Medicine ,long-term treatment ,migraine ,Longitudinal Studies ,education ,allodynia ,education.field_of_study ,business.industry ,Middle Aged ,medicine.disease ,Italy ,Neurology ,Tolerability ,Migraine ,erenumab ,Hyperalgesia ,Chronic Disease ,Female ,Neurology (clinical) ,business ,Human - Abstract
Objective: To evaluate the long-term effectiveness, safety, and tolerability of erenumab in a real-world migraine population, looking for putative predictors of responsiveness. Background: Erenumab proved to be effective, safe, and well tolerated in the prevention of episodic migraine (EM) and chronic migraine (CM) in long-term extension studies of double-blind, placebo-controlled trials in patients with no more than two (EM) or three (CM) prior preventive treatment failures. Methods: A 48-week, multicenter, longitudinal cohort real-life study was conducted at 15headache centers across eight Italian regions between December 20, 2018 and July 31, 2020. We considered all consecutive patients with high-frequency episodic migraine (HFEM) or CM aged 18–65years. Each patient was treated with erenumab 70mg, administered monthly. The dose was switched to 140mg in nonresponders and in responders who had become nonresponders for at least 4weeks. Change in monthly migraine days (MMDs) or monthly headache days (MHDs) at Weeks 45–48 compared with baseline was the primary efficacy endpoint. Secondary endpoints encompassed variation in monthly analgesic intake, achievement of a ≥50%, ≥75%, or 100% reduction in migraine or headache days, and any change in the Visual Analogue Scale (VAS) and Headache Impact Test-6 scores (HIT-6) during the same time interval. Results: A total of 242 patients with migraine received at least one dose of erenumab 70mg and were considered for safety analysis, whereas 221 received a monthly erenumab dose for ≥48weeks and were included in the effectiveness and safety analysis set. All patients had previously been treated unsuccessfully with ≥3migraine-preventive medication classes. From baseline to Weeks 45–48, erenumab treatment reduced MMD by 4.3±5.3(mean±SD) in patients with HFEM, and MHD by 12.8±8.9 (mean±SD) in subjects with CM. VAS and HIT-6scores were decreased by 1.8±1.9 (mean±SD) and 12.3±11 (mean±SD) in HFEM, and by 3.0±2.2 (mean±SD) and 13.1±11.2 (mean±SD) in CM. Median monthly analgesic intake passed from 11.0 (interquartile range [IQR] 10.0–13.0) to 5 (IQR 2.0–8.0) in HFEM and from 20.0 (IQR 15.0–30.0) to 6.0 (IQR 3.8–10.0) in CM. The ≥50% responders were 56.1% (32/57) in HFEM and 75.6% (124/164) in CM; ≥75% responders were 31.6% (18/57) and 44.5% (73/164); and 100% responders were 8.8% (5/57) and 1.2% (2/164), respectively. At Week 48, 83.6% (137/164) of patients with CM had reverted to EM. Erenumab was safe and well tolerated. Responsiveness to erenumab was positively associated with cutaneous allodynia (OR: 5.44, 95% CI: 1.52–19.41; p=0.009) in HFEM. In patients with CM, ≥50% responsiveness was positively associated with male sex (OR: 2.99, 95% CI: 1.03–8.7; p=0.044) and baseline migraine frequency (OR: 1.12, 95% CI: 1.05–1.20; p=0.001) and negatively associated with psychiatric comorbidities (OR: 0.37, 95% CI: 0.15–0.87; p=0.023) and prior treatment failures (OR: 0.77, 95% CI: 0.64–0.92; p=0.004). Conclusions: Long-term (48-week) erenumab treatment provides sustained effectiveness, safety, and tolerability in real-life patients with HFEM or CM with ≥3 prior preventive treatment failures. The dose of 140mg was required in most patients along the study and should be taken into consideration as the starting dose. Allodynia (in HFEM), male sex, and baseline migraine frequency (in CM) might represent positive responsiveness predictors. Conversely, psychiatric comorbidities and multiple prior preventive treatment failures could be negative predictors in patients with CM.
- Published
- 2021
11. Structure of yeast Sec14p with NPPM481
- Author
-
Hong, Z., primary, Johnen, P., additional, Schaaf, G., additional, and Bono, F., additional
- Published
- 2023
- Full Text
- View/download PDF
12. Structure of yeast Sec14p with ergoline
- Author
-
Hong, Z., primary, Johnen, P., additional, Schaaf, G., additional, and Bono, F., additional
- Published
- 2023
- Full Text
- View/download PDF
13. Structure of yeast Sec14p with himbacine
- Author
-
Hong, Z., primary, Johnen, P., additional, Schaaf, G., additional, and Bono, F., additional
- Published
- 2023
- Full Text
- View/download PDF
14. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
- Author
-
Canova, S., primary, Ceresoli, G.L., additional, Grosso, F., additional, Zucali, P.A., additional, Gelsomino, F., additional, Pasello, G., additional, Mencoboni, M., additional, Rulli, E., additional, Galli, F., additional, De Simone, I., additional, Carlucci, L., additional, De Angelis, A., additional, Belletti, M., additional, Bonomi, M., additional, D’Aveni, A., additional, Perrino, M., additional, Bono, F., additional, Cortinovis, D.L., additional, Cortinovis, D., additional, Canova, S., additional, Colonese, F., additional, Abbate, M.I., additional, Sala, L., additional, Sala, E., additional, Perez Gila, M., additional, Pagni, F., additional, Ugo, F., additional, De Vincenzo, F., additional, Santoro, A., additional, Ardizzoni, A., additional, Frega, S., additional, D’Incalci, M., additional, Poli, D., additional, and Torri, V., additional
- Published
- 2022
- Full Text
- View/download PDF
15. Indirect structural health monitoring (iSHM) of transport infrastructure in the digital age. MITICA (Monitoring Transport Infrastructures with Connected and Automated vehicles) workshop report
- Author
-
Gkoumas, Konstantinos, Galassi, M.C., Allaix, Diego, Anthonine, A, Argyroudis, S., Baldini, G, Benedetti, Lorenzo, Bono, F, Brownjohn, James, Caetano, Elsa, Camata, G, Cantero, Daniel, Cimellaro, G.P., and Cutini, Maurizio
- Abstract
The existing European motorway infrastructure network is prone to ageing and subject to natural events (e.g. climate change) and hazards (e.g. earthquakes), necessitating immediate actions for its maintenance and safety. Within this context, the structural health monitoring (SHM) framework allows a quantitative assessment of the structural integrity, serviceability and performance, facilitating better-informed decisions for the management of the existing infrastructure. The European Commission Joint Research Centre (JRC) established the exploratory research project MITICA (Monitoring Transport Infrastructures with Connected and Automated vehicles) to investigate the opportunity to use novel methods for infrastructure motoring, aiming at the efficient maintenance of the European aging road infrastructure. This report summarizes the discussion and the outcomes of a workshop held at the JRC in Ispra (Italy) on June 6-7 2022, as part of the MITICA project. Considering the EU priority “A Europe fit for the digital age”, the workshop was dedicated to SHM and its application to civil infrastructure, focusing on innovative indirect structural health monitoring (iSHM) approaches that rely on the vehicle-bridge interaction and the deployment of sensor-equipped vehicles for the monitoring of the existing bridge infrastructure. The report aims to become a reference document in the area of iSHM using passing vehicles, for both scholars and policy makers.
- Published
- 2023
16. Phenotypic Variability in Acquired and Idiopathic Dystonia
- Author
-
Defazio, G, Gigante, Af, Erro, R, Belvisi, D, Esposito, M, Trinchillo, A, De Joanna, G, Ceravolo, R, Mazzucchi, S, Unti, E, Barone, P, Scannapieco, S, Cotelli, Ms, Turla, M, Bianchi, M, Bertolasi, L, Pisani, A, Valentino, F, Altavista, Mc, Moschella, V, Girlanda, P, Terranova, C, Bono, F, Spano, G, Fabbrini, G, Ferrazzano, G, Albanese, A, Castagna, A, Cassano, D, Moja, Mc, Pellicciari, R, Bentivoglio, Ar, Eleopra, R, Cossu, G, Ercoli, T, Mascia, Mm, Di Biasio, F, Misceo, S, Magistrelli, L, Romano, M, Scaglione, Clm, Tinazzi, M, Maderna, L, Zibetti, M, and Berardelli, A
- Subjects
clinical phenomenology ,acquired ,idiopathic ,dystonia - Published
- 2023
17. The Italian Dystonia Registry: rationale, design and preliminary findings
- Author
-
Defazio, Giovanni, Esposito, M., Abbruzzese, G., Scaglione, C. L., Fabbrini, G., Ferrazzano, G., Peluso, S., Pellicciari, R., Gigante, A. F., Cossu, G., Arca, R., Avanzino, L., Bono, F., Mazza, M. R., Bertolasi, L., Bacchin, R., Eleopra, R., Lettieri, C., Morgante, F., Altavista, M. C., Polidori, L., Liguori, R., Misceo, S., Squintani, G., Tinazzi, M., Ceravolo, R., Unti, E., Magistrelli, L., Coletti Moja, M., Modugno, N., Petracca, M., Tambasco, N., Cotelli, M. S., Aguggia, M., Pisani, A., Romano, M., Zibetti, M., Bentivoglio, A. R., Albanese, A., Girlanda, P., and Berardelli, A.
- Published
- 2017
- Full Text
- View/download PDF
18. Malignant Pleural Mesothelioma in situ is a reality: how to handle this?
- Author
-
Raveglia, F, primary, Orlandi, R, additional, Bono, F, additional, Solli, P, additional, Cardillo, G, additional, Libretti, L, additional, Tuoro, A, additional, Cassina, E M, additional, Caruana, E, additional, and Scarci, M, additional
- Published
- 2022
- Full Text
- View/download PDF
19. SAR216471, an alternative to the use of currently available P2Y12 receptor inhibitors?
- Author
-
Delesque-Touchard, N., Pflieger, A.M., Bonnet-Lignon, S., Millet, L., Salel, V., Boldron, C., Lassalle, G., Herbert, J.M., Savi, P., and Bono, F.
- Published
- 2014
- Full Text
- View/download PDF
20. Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases
- Author
-
Andreano, A, Valsecchi, M, Russo, A, Siena, S, Andruccioli, M, Ardizzoia, A, Assi, A, Baisi, A, Bedini, A, Beretta, G, Bersani, M, Bertagna, F, Berti, E, Bertolini, A, Bettini, A, Bignardi, M, Bini, F, Bna, C, Bono, F, Ottoni, D, Borghesi, A, Borghetti, P, Brunelli, A, Buffoli, A, Cacioppo, C, Calati, A, Calcagno, A, Casagrande, S, Casartelli, C, Castellani, M, Castro, A, Catalano, G, Catena, L, Ceresoli, G, Cergnul, M, Ciocia, G, Colombo, A, Conti, B, Corti, D, Cortinovis, D, Cozzi, C, Crippa, F, De Monte, A, Candis, D, De Toma, D, De Marinis, F, Dimarco, B, Di Nuovo, F, Doglioni, C, Fabbris, V, Faccioli, P, Fagnani, D, Farina, G, Fariselli, L, Filipazzi, V, Franzi, F, Frata, P, Gajate, A, Gardani, G, Gasparini, M, Giordano, M, Grignani, F, Landoni, C, Lombardi, C, Lombardi, F, Luciani, A, Maffioli, L, Marchione, R, Mariani, P, Maspero, A, Meriggi, F, Miedico, A, Morbini, P, Muriana, G, Orlandoni, G, Paris, E, Pedrazzoli, P, Pepe, G, Pezzica, E, Piccoli, F, Pinotti, G, Quadri, A, Ravasio, A, Ravenna, F, Ricchiuti, E, Rinaldo, D, Roda, G, Rossi, G, Santoro, A, Soatti, C, Stiglich, F, Tagliabue, L, Tirelli, V, Tironi, A, Tomirotti, M, Travaini, L, Ucci, G, Vaghi, A, Vanzulli, A, Veronesi, G, Vittimberga, I, Zambelli, C, Andreano A., Valsecchi M. G., Russo A. G., Siena S., Andruccioli M., Ardizzoia A., Assi A., Baisi A., Bedini A. V., Beretta G., Bersani M., Bertagna F., Berti E., Bertolini A., Bettini A., Bignardi M., Bini F., Bna C., Bono F., Ottoni D. B., Borghesi A., Borghetti P., Brunelli A., Buffoli A., Cacioppo C., Calati A., Calcagno A., Casagrande S., Casartelli C., Castellani M., Castro A., Catalano G., Catena L., Ceresoli G. L., Cergnul M., Ciocia G., Colombo A., Conti B., Corti D., Cortinovis D., Cozzi C., Crippa F., De Monte A., Candis D. D., De Toma D., De Marinis F., DiMarco B., Di Nuovo F., Doglioni C., Fabbris V., Faccioli P., Fagnani D., Farina G., Fariselli L., Filipazzi V., Franzi F., Frata P., Gajate A. M. S., Gardani G., Gasparini M., Giordano M., Grignani F., Landoni C., Lombardi C., Lombardi F., Luciani A., Maffioli L. S., Marchione R., Mariani P., Maspero A., Meriggi F., Miedico A., Morbini P., Muriana G., Orlandoni G., Paris E., Pedrazzoli P., Pepe G., Pezzica E., Piccoli F., Pinotti G., Quadri A., Ravasio A., Ravenna F., Ricchiuti E., Rinaldo D., Roda G., Rossi G., Santoro A., Soatti C. P., Stiglich F., Tagliabue L., Tirelli V., Tironi A., Tomirotti M., Travaini L. L., Ucci G., Vaghi A., Vanzulli A., Veronesi G., Vittimberga I., Zambelli C., Andreano, A, Valsecchi, M, Russo, A, Siena, S, Andruccioli, M, Ardizzoia, A, Assi, A, Baisi, A, Bedini, A, Beretta, G, Bersani, M, Bertagna, F, Berti, E, Bertolini, A, Bettini, A, Bignardi, M, Bini, F, Bna, C, Bono, F, Ottoni, D, Borghesi, A, Borghetti, P, Brunelli, A, Buffoli, A, Cacioppo, C, Calati, A, Calcagno, A, Casagrande, S, Casartelli, C, Castellani, M, Castro, A, Catalano, G, Catena, L, Ceresoli, G, Cergnul, M, Ciocia, G, Colombo, A, Conti, B, Corti, D, Cortinovis, D, Cozzi, C, Crippa, F, De Monte, A, Candis, D, De Toma, D, De Marinis, F, Dimarco, B, Di Nuovo, F, Doglioni, C, Fabbris, V, Faccioli, P, Fagnani, D, Farina, G, Fariselli, L, Filipazzi, V, Franzi, F, Frata, P, Gajate, A, Gardani, G, Gasparini, M, Giordano, M, Grignani, F, Landoni, C, Lombardi, C, Lombardi, F, Luciani, A, Maffioli, L, Marchione, R, Mariani, P, Maspero, A, Meriggi, F, Miedico, A, Morbini, P, Muriana, G, Orlandoni, G, Paris, E, Pedrazzoli, P, Pepe, G, Pezzica, E, Piccoli, F, Pinotti, G, Quadri, A, Ravasio, A, Ravenna, F, Ricchiuti, E, Rinaldo, D, Roda, G, Rossi, G, Santoro, A, Soatti, C, Stiglich, F, Tagliabue, L, Tirelli, V, Tironi, A, Tomirotti, M, Travaini, L, Ucci, G, Vaghi, A, Vanzulli, A, Veronesi, G, Vittimberga, I, Zambelli, C, Andreano A., Valsecchi M. G., Russo A. G., Siena S., Andruccioli M., Ardizzoia A., Assi A., Baisi A., Bedini A. V., Beretta G., Bersani M., Bertagna F., Berti E., Bertolini A., Bettini A., Bignardi M., Bini F., Bna C., Bono F., Ottoni D. B., Borghesi A., Borghetti P., Brunelli A., Buffoli A., Cacioppo C., Calati A., Calcagno A., Casagrande S., Casartelli C., Castellani M., Castro A., Catalano G., Catena L., Ceresoli G. L., Cergnul M., Ciocia G., Colombo A., Conti B., Corti D., Cortinovis D., Cozzi C., Crippa F., De Monte A., Candis D. D., De Toma D., De Marinis F., DiMarco B., Di Nuovo F., Doglioni C., Fabbris V., Faccioli P., Fagnani D., Farina G., Fariselli L., Filipazzi V., Franzi F., Frata P., Gajate A. M. S., Gardani G., Gasparini M., Giordano M., Grignani F., Landoni C., Lombardi C., Lombardi F., Luciani A., Maffioli L. S., Marchione R., Mariani P., Maspero A., Meriggi F., Miedico A., Morbini P., Muriana G., Orlandoni G., Paris E., Pedrazzoli P., Pepe G., Pezzica E., Piccoli F., Pinotti G., Quadri A., Ravasio A., Ravenna F., Ricchiuti E., Rinaldo D., Roda G., Rossi G., Santoro A., Soatti C. P., Stiglich F., Tagliabue L., Tirelli V., Tironi A., Tomirotti M., Travaini L. L., Ucci G., Vaghi A., Vanzulli A., Veronesi G., Vittimberga I., and Zambelli C.
- Abstract
Background: To identify indicators of guideline-concordant care in lung cancer, to implement such indicators with cancer registry data linked to health databases, and to pilot them in a cohort of patients from the cancer registry of the Milan Province. Methods: Thirty-four indicators were selected by revision of main guidelines by cancer epidemiologists, and then evaluated by a multidisciplinary panel of clinicians involved in lung cancer care and working on the pathway of lung cancer diagnosis and treatment in the Lombardy region, Italy. With a modified Delphi method, they assessed for each indicator the content validity as a quality measure of the care pathway, the degree of modifiability from the health professional, and the relevance to the health professional. Feasibility was assessed using the cancer registry and the routine health records of the Lombardy region. Feasible indicators were then calculated in the cohort of lung cancer patients diagnosed in 2007–2012 derived from the cancer registry of the Milan Province. Criterion validity was assessed reviewing clinical records of a random sample of 114 patients (threshold for acceptable discordance ≤20%). Finally, reliability was evaluated at the provider level. Results: Initially, 34 indicators were proposed for evaluation in the first Delphi round. Of the finally 22 selected indicators, 3 were not feasible because the required information was actually not available. The remaining 19 were calculated on the pilot cohort. After assessment of criterion validity (3 eliminated), 16 indicators were retained in the final set and evaluated for reliability. Conclusion: The developed and piloted set of indicators is now available to implement and monitor, over time, quality initiatives for lung cancer care in the studied health system.
- Published
- 2021
21. Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor
- Author
-
Bono, F, Mutti, V, Piovani, G, Minelli, A, Mingardi, J, Guglielmi, A, Missale, C, Gennarelli, M, Fiorentini, C, Barbon, A, Bono F., Mutti V., Piovani G., Minelli A., Mingardi J., Guglielmi A., Missale C., Gennarelli M., Fiorentini C., Barbon A., Bono, F, Mutti, V, Piovani, G, Minelli, A, Mingardi, J, Guglielmi, A, Missale, C, Gennarelli, M, Fiorentini, C, Barbon, A, Bono F., Mutti V., Piovani G., Minelli A., Mingardi J., Guglielmi A., Missale C., Gennarelli M., Fiorentini C., and Barbon A.
- Abstract
Peripheral blood mononuclear cells (PBMCs) derived from a healthy 40-year-old female were successfully transformed into induced pluripotent stem cells (iPSCs) by using the integration-free CytoTune-iPS Sendai Reprogramming method. The resulting iPSCs line exhibits a normal karyotype, expresses stemness markers and displays the differentiation capacity into the three germ layers. This human iPSCs line can be used as healthy control in disease modelling studies.
- Published
- 2021
22. Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson's Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice
- Author
-
Casiraghi, A., Longhena, F., Faustini, G., Ribaudo, G., Suigo, L., Camacho-Hernandez, G. A., Bono, F., Brembati, V., Newman, A. H., Gianoncelli, A., Straniero, V., Bellucci, A., and Valoti, E.
- Subjects
threo methyl 2-(piperidin-2-yl)-2-(p-tolyl)acetate hydrochloride ,α-synuclein/synapsin III complex ,motor recovery effect ,methylphenidate analogues ,Parkinson’s disease - Abstract
Parkinson's disease (PD) is characterized by dopaminergic nigrostriatal neurons degeneration and Lewy body pathology, mainly composed of α-synuclein (αSyn) fibrillary aggregates. We recently described that the neuronal phosphoprotein Synapsin III (Syn III) participates in αSyn pathology in PD brains and is a permissive factor for αSyn aggregation. Moreover, we reported that the gene silencing of Syn III in a human αSyn transgenic (tg) mouse model of PD at a pathological stage, manifesting marked insoluble αSyn deposits and dopaminergic striatal synaptic dysfunction, could reduce αSyn aggregates, restore synaptic functions and motor activities and exert neuroprotective effects. Interestingly, we also described that the monoamine reuptake inhibitor methylphenidate (MPH) can recover the motor activity of human αSyn tg mice through a dopamine (DA) transporter-independent mechanism, which relies on the re-establishment of the functional interaction between Syn III and α-helical αSyn. These findings support that the pathological αSyn/Syn III interaction may constitute a therapeutic target for PD. Here, we studied MPH and some of its analogues as modulators of the pathological αSyn/Syn III interaction. We identified 4-methyl derivative
- Published
- 2022
23. Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression
- Author
-
Bono, F, Mutti, V, Piovani, G, Minelli, A, Mingardi, J, Guglielmi, A, Fiorentini, C, Barbon, A, Missale, C, Gennarelli, M, Bono F., Mutti V., Piovani G., Minelli A., Mingardi J., Guglielmi A., Fiorentini C., Barbon A., Missale C., Gennarelli M., Bono, F, Mutti, V, Piovani, G, Minelli, A, Mingardi, J, Guglielmi, A, Fiorentini, C, Barbon, A, Missale, C, Gennarelli, M, Bono F., Mutti V., Piovani G., Minelli A., Mingardi J., Guglielmi A., Fiorentini C., Barbon A., Missale C., and Gennarelli M.
- Abstract
Novel and complementary experimental models are required for investigating the molecular mechanisms underlying the resistance to the available therapies of patients with major depression (Treatment-Resistant Depression, TRD) that occurs in at least one third of patients and need to be deeply investigated. Here, we have established a patient-specific disease model for TRD by reprogramming peripheral blood mononuclear cells (PBMCs) from two TRD patients into induced pluripotent stem cells (iPSCs), using non-integrating Sendai virus. These lines show the typical morphology of pluripotent cells, express pluripotency markers and displayed in vitro differentiation potential toward cells of the three embryonic germ layers.
- Published
- 2020
24. Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy
- Author
-
Massironi, S, Vigano, C, Dioscoridi, L, Filippi, E, Pagliarulo, M, Manfredi, G, Conti, C, Signorelli, C, Redaelli, A, Bonato, G, Iiritano, E, Frego, R, Zucchini, N, Ungari, M, Pedaci, M, Bono, F, Di Bella, C, Buscarini, E, Mutignani, M, Penagini, R, Dinelli, M, Invernizzi, P, Massironi S., Vigano C., Dioscoridi L., Filippi E., Pagliarulo M., Manfredi G., Conti C. B., Signorelli C., Redaelli A. E., Bonato G., Iiritano E., Frego R., Zucchini N., Ungari M., Pedaci M., Bono F., Di Bella C., Buscarini E., Mutignani M., Penagini R., Dinelli M. E., Invernizzi P., Massironi, S, Vigano, C, Dioscoridi, L, Filippi, E, Pagliarulo, M, Manfredi, G, Conti, C, Signorelli, C, Redaelli, A, Bonato, G, Iiritano, E, Frego, R, Zucchini, N, Ungari, M, Pedaci, M, Bono, F, Di Bella, C, Buscarini, E, Mutignani, M, Penagini, R, Dinelli, M, Invernizzi, P, Massironi S., Vigano C., Dioscoridi L., Filippi E., Pagliarulo M., Manfredi G., Conti C. B., Signorelli C., Redaelli A. E., Bonato G., Iiritano E., Frego R., Zucchini N., Ungari M., Pedaci M., Bono F., Di Bella C., Buscarini E., Mutignani M., Penagini R., Dinelli M. E., and Invernizzi P.
- Abstract
Coronavirus disease 2019 (COVID-19) is a major worldwide threat caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rapidly spreading to a global pandemic. As of May 11, 2020, 4,176,346 cases have been reported worldwide, 219,814 in Italy, and of them, 81,871 occurred in the Lombardy region.1 Although the respiratory manifestations of COVID-19 have been widely described, the impact on the gastrointestinal (GI) system remains less clear. The reported prevalence of digestive symptoms ranges from 3% to 79%, depending on the setting,2–5 but data on GI endoscopic and histologic findings in COVID-19 patients are lacking. Therefore, the aim of this study is to describe the GI endoscopic and histologic findings in COVID-19 patients.
- Published
- 2020
25. A deep learning approach for fault detection and RUL estimation in bearings
- Author
-
Bono, F. M., Cinquemani, S., Chatterton, S., and Pennacchi, P.
- Published
- 2022
26. HEADWORK Questionnaire: Why Do We Need a New Tool to Assess Work-Related Disability in Patients With Migraine?
- Author
-
D'Amico D., Grazzi L., Grignani E., Leonardi M., Sansone E., Raggi A., Covelli V., Guastafierro E., Scaratti C., Usai S., Bartolini M., Viticchi G., Cevoli S., Pierangeli G., Tedeschi G., Russo A., Barbanti P., Aurilia C., Lovati C., Giani L., Frediani F., Di Fiore P., Bono F., Rapisarda L., Pascarella A., D'Amico, D., Grazzi, L., Grignani, E., Leonardi, M., Sansone, E., Raggi, A., Covelli, V., Guastafierro, E., Scaratti, C., Usai, S., Bartolini, M., Viticchi, G., Cevoli, S., Pierangeli, G., Tedeschi, G., Russo, A., Barbanti, P., Aurilia, C., Lovati, C., Giani, L., Frediani, F., Di Fiore, P., Bono, F., Rapisarda, L., Pascarella, A., D'Amico D., Grazzi L., Grignani E., Leonardi M., Sansone E., Raggi A., Covelli V., Guastafierro E., Scaratti C., Usai S., Bartolini M., Viticchi G., Cevoli S., Pierangeli G., Tedeschi G., Russo A., Barbanti P., Aurilia C., Lovati C., Giani L., Frediani F., Di Fiore P., Bono F., Rapisarda L., and Pascarella A.
- Subjects
Adult ,Gerontology ,medicine.medical_specialty ,disability evaluation ,Migraine Disorders ,Severity of Illness Index ,Work related ,03 medical and health sciences ,Indirect costs ,0302 clinical medicine ,Chronic Migraine ,work ,Surveys and Questionnaires ,Epidemiology ,Humans ,Medicine ,Disabled Persons ,In patient ,030212 general & internal medicine ,Sensitivity to change ,HEADWORK ,business.industry ,medicine.disease ,Clinical trial ,Neurology ,Migraine ,employment ,episodic migraine ,Neurology (clinical) ,chronic migraine ,business ,030217 neurology & neurosurgery - Abstract
Objective: This article reviews current headache disability measures and clinical need, as well as presenting the rationale for a new measure addressing work-related disability in migraine patients and the steps devoted to this aim. Background: Episodic and chronic migraine (EM and CM) constitute an enormous economic burden to societies, and the vast majority of this burden is attributable to indirect costs, ie those associated with productivity loss. A measure of work-related disability is therefore needed to quantify the impact of EM and CM on patients' ability to carry out work tasks. Methods: We briefly present the advantages and disadvantages of the disability measures that have been most commonly used for this purpose and the rationale for developing a new measure. Results: The entire process of development of HEADWORK, a questionnaire designed to assess work-related disability, is presented together with short-term sensitivity to change. Conclusions: Current headache disability measures need improvement. HEADWORK is a valid, reliable, and sensitive questionnaire to address the amount and severity of work-related difficulties and of the factors contributing to such difficulties. HEADWORK is suitable for daily clinical practice, epidemiological research and for clinical trials, and potentially to define work-related disability weights for the calculation of migraine indirect costs.
- Published
- 2020
27. The 'digital biopsy' in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT
- Author
-
Monaco, L, De Bernardi, E, Bono, F, Cortinovis, D, Crivellaro, C, Elisei, F, L'Imperio, V, Landoni, C, Mathoux, G, Musarra, M, Pagni, F, Turolla, E, Messa, C, Guerra, L, Monaco, Lavinia, De Bernardi, Elisabetta, Bono, Francesca, Cortinovis, Diego, Crivellaro, Cinzia, Elisei, Federica, L'Imperio, Vincenzo, Landoni, Claudio, Mathoux, Gregory, Musarra, Monica, Pagni, Fabio, Turolla, Elia Anna, Messa, Cristina, Guerra, Luca, Monaco, L, De Bernardi, E, Bono, F, Cortinovis, D, Crivellaro, C, Elisei, F, L'Imperio, V, Landoni, C, Mathoux, G, Musarra, M, Pagni, F, Turolla, E, Messa, C, Guerra, L, Monaco, Lavinia, De Bernardi, Elisabetta, Bono, Francesca, Cortinovis, Diego, Crivellaro, Cinzia, Elisei, Federica, L'Imperio, Vincenzo, Landoni, Claudio, Mathoux, Gregory, Musarra, Monica, Pagni, Fabio, Turolla, Elia Anna, Messa, Cristina, and Guerra, Luca
- Abstract
Purpose: The present pilot study investigates the putative role of radiomics from [18F]FDG PET/CT scans to predict PD-L1 expression status in non-small cell lung cancer (NSCLC) patients. Methods: In a retrospective cohort of 265 patients with biopsy-proven NSCLC, 86 with available PD-L1 immunohistochemical (IHC) assessment and [18F]FDG PET/CT scans have been selected to find putative metabolic markers that predict PD-L1 status (< 1%, 1–49%, and ≥ 50% as per tumor proportion score, clone 22C3). Metabolic parameters have been extracted from three different PET/CT scanners (Discovery 600, Discovery IQ, and Discovery MI) and radiomics features were computed with IBSI compliant algorithms on the original image and on images filtered with LLL and HHH coif1 wavelet, obtaining 527 features per tumor. Univariate and multivariate analysis have been performed to compare PD-L1 expression status and selected radiomic features. Results: Of the 86 analyzed cases, 46 (53%) were negative for PD-L1 IHC, 13 (15%) showed low PD-L1 expression (1–49%), and 27 (31%) were strong expressors (≥ 50%). Maximum standardized uptake value (SUVmax) demonstrated a significant ability to discriminate strong expressor cases at univariate analysis (p = 0.032), but failed to discriminate PD-L1 positive patients (PD-L1 ≥ 1%). Three radiomics features appeared the ablest to discriminate strong expressors: (1) a feature representing the average high frequency lesion content in a spherical VOI (p = 0.009); (2) a feature assessing the correlation between adjacent voxels on the high frequency lesion content (p = 0.004); (3) a feature that emphasizes the presence of small zones with similar grey levels inside the lesion (p = 0.003). The tri-variate linear discriminant model combining the three features achieved a sensitivity of 81% and a specificity of 82% in the test. The ability of radiomics to predict PD-L1 positive patients was instead scarce. Conclusions: Our data indicate a possible role of the [18F]
- Published
- 2022
28. Activities of the European Laboratory for Structural Assessment for Seismic Risk Reduction in Europe
- Author
-
Renda, V., Verzeletti, G., Magonette, G., Molina, J., Tirelli, D., Bono, F., Balassanian, Serguei, editor, Cisternas, Armando, editor, and Melkumyan, Mikael, editor
- Published
- 2000
- Full Text
- View/download PDF
29. A comparison between regular and physics-informed neural networks based on a numerical multibody model: a test case for the synthesis of mechanisms
- Author
-
Meyendorf, Norbert G., Niezrecki, Christopher, Singh, Ripi, Bono, F. M., Radicioni, L., and Cinquemani, S.
- Published
- 2023
- Full Text
- View/download PDF
30. An approach based on convolutional autoencoder for detecting damage location in a mechanical system
- Author
-
Meyendorf, Norbert G., Niezrecki, Christopher, Singh, Ripi, Bono, F. M., Radicioni, L., Bombaci, G., Somaschini, C., and Cinquemani, S.
- Published
- 2023
- Full Text
- View/download PDF
31. Improving the effectiveness of anomaly detection in bridges through a deep learning method based on the coherence of signals
- Author
-
Meyendorf, Norbert G., Niezrecki, Christopher, Singh, Ripi, Bono, F. M., Radicioni, L., Benedetti, L., Cazzulani, G., Meregalli, S., Cinquemani, S., and Belloli, M.
- Published
- 2023
- Full Text
- View/download PDF
32. Overcoming strain gauges limitation in the estimation of train load passing on a bridge through deep learning
- Author
-
Meyendorf, Norbert G., Niezrecki, Christopher, Singh, Ripi, Radicioni, L., Bono, F. M., Benedetti, L., Argentino, A., Somaschini, C., Cinquemani, S., and Belloli, M.
- Published
- 2023
- Full Text
- View/download PDF
33. Randomised trial comparing Lichtenstein vs Trabucco vs Valenti techniques in inguinal hernia repair
- Author
-
Ripetti, V., La Vaccara, V., Greco, S., Bono, F., Valeri, S., and Coppola, R.
- Published
- 2014
- Full Text
- View/download PDF
34. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells
- Author
-
Scotland, S, Saland, E, Skuli, N, de Toni, F, Boutzen, H, Micklow, E, Sénégas, I, Peyraud, R, Peyriga, L, Théodoro, F, Dumon, E, Martineau, Y, Danet-Desnoyers, G, Bono, F, Rocher, C, Levade, T, Manenti, S, Junot, C, Portais, J-C, Alet, N, Récher, C, Selak, M A, Carroll, M, and Sarry, J-E
- Published
- 2013
- Full Text
- View/download PDF
35. Idiopathic Non-Task-Specific Upper Limb Dystonia, a Neglected Form of Dystonia
- Author
-
Defazio, G., Ercoli, T., Erro, R., Pellicciari, R., Mascia, M. M., Fabbrini, G., Albanese, A., Lalli, S., Eleopra, R., Barone, P., Marchese, R., Ceravolo, R., Scaglione, C., Liguori, R., Esposito, M., Bentivoglio, A. R., Bertolasi, L., Altavista, M. C., Bono, F., Pisani, A., Girlanda, P., Berardelli, A., Italian Dystonia Registry, Ferrazzano, G., Defazio G., Ercoli T., Erro R., Pellicciari R., Mascia M.M., Fabbrini G., Albanese A., Lalli S., Eleopra R., Barone P., Marchese R., Ceravolo R., Scaglione C., Liguori R., Esposito M., Bentivoglio A.R., Bertolasi L., Altavista M.C., Bono F., Pisani A., Girlanda P., and Berardelli A.
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,upper limb ,writer's cramp ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Tremor ,medicine ,otorhinolaryngologic diseases ,Humans ,Family history ,Sensory trick ,Retrospective Studies ,Dystonia ,business.industry ,Writer's cramp ,Retrospective cohort study ,dystonia ,non-task-specificity ,task-specificity ,Focal dystonia ,medicine.disease ,Action tremor ,nervous system diseases ,Settore MED/26 - NEUROLOGIA ,030104 developmental biology ,medicine.anatomical_structure ,Neurology ,Italy ,Dystonic Disorders ,Upper limb ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Objective The objective of this study was to describe the clinical and demographic features of idiopathic non-task-specific upper limb dystonia compared with the task-specific form. Methods In this retrospective study, adult patients with idiopathic upper limb dystonia, either focal or as part of a segmental/multifocal dystonia, from the Italian Dystonia Registry were enrolled. In patients with focal upper limb dystonia, dystonia spread was estimated by survival analysis. Results Of the 1522 patients with idiopathic adult-onset dystonia included in the Italian Dystonia Registry, we identified 182 patients with upper limb dystonia. Non-task-specific dystonia was present in 61.5% of enrolled cases. Women predominated among non-task-specific patients, whereas men predominated in the task-specific group. Peak age of upper limb dystonia onset was in the sixth decade in the non-task-specific group and in the fourth decade in the task-specific group. In both groups, upper limb dystonia started as focal dystonia or as part of a segmental dystonia. Segmental onset was more frequent among non-task-specific patients, whereas focal onset predominated among task-specific patients. Dystonic action tremor was more frequent among non-task-specific patients. No significant differences between groups emerged in terms of sensory trick frequency, rest tremor, or family history of dystonia. In patients with focal upper limb dystonia, dystonia spread was greater in the non-task-specific group. Conclusion Novel information on upper limb dystonia patients suggests that non-task-specific and task-specific upper limb dystonia have different demographic and clinical features. However, it remains to be determined whether these differences also reflect pathophysiological differences. © 2020 International Parkinson and Movement Disorder Society.
- Published
- 2020
36. Implementation of a wireless instrumented sphere for fruit processing
- Author
-
Alleri M., Bono F., Catania P., Roma E., Vallone M., Alleri M., Bono F., Catania P., Roma E., and Vallone M.
- Subjects
electronic fruit, post harvest, triaxial accelerometer ,Settore AGR/09 - Meccanica Agraria - Abstract
The aim of this study was to implement a wireless instrumented sphere to study the critical points in a citrus packing line by real-time measuring the impacts experienced by fruits. The noncommercial device was based on a MEMS (microelectro-mechanical system) sensor node with a sensing range from ±1 g to ±400 g (g = 9.8 m s-2), a ferroelectric RAM (FRAM) memory, a radio frequency (RF) transmitter, a microcontroller, and a 75 mAh lithium battery. The sensor node was placed inside an appropriate case with a total weight of 100 g to represent a 'Tardivo di Ciaculli' mandarin. An FR receiver allowed real-time transmission of the measured data. Total acceleration values, representing the stresses experienced by fruit, were studied. The results showed that total acceleration remained below 20 g in most of the measurements, but considerably higher values, up to 80 g, were obtained between the brushing and waxing machines.
- Published
- 2020
37. Correction to: The Italian Dystonia Registry: rationale, design and preliminary findings
- Author
-
Defazio, Giovanni, Esposito, M., Abbruzzese, G., Scaglione, C. L., Fabbrini, G., Ferrazzano, G., Peluso, S., Pellicciari, R., Gigante, A. F., Cossu, G., Arca, R., Avanzino, L., Bono, F., Mazza, M. R., Bertolasi, L., Bacchin, R., Eleopra, R., Lettieri, C., Morgante, F., Altavista, M. C., Polidori, L., Liguori, R., Misceo, S., Squintani, G., Tinazzi, M., Ceravolo, R., Unti, E., Magistrelli, L., Coletti Moja, M., Modugno, N., Petracca, M., Tambasco, N., Cotelli, M. S., Aguggia, M., Pisani, A., Romano, M., Zibetti, M., Bentivoglio, A. R., Albanese, A., Girlanda, P., and Berardelli, A.
- Published
- 2018
- Full Text
- View/download PDF
38. Proteomics for the diagnosis of thyroid lesions: preliminary report
- Author
-
Pagni, F., Mainini, V., Garancini, M., Bono, F., Vanzati, A., Giardini, V., Scardilli, M., Goffredo, P., Smith, A. J., Galli, M., De Sio, G., and Magni, F.
- Published
- 2015
- Full Text
- View/download PDF
39. miR-9-5p is involved in the rescue of stress-dependent dendritic shortening of hippocampal pyramidal neurons induced by acute antidepressant treatment with ketamine
- Author
-
Mingardi, J, La Via, L, Tornese, P, Carini, G, Trontti, K, Seguini, M, Tardito, D, Bono, F, Fiorentini, C, Elia, L, Hovatta, I, Popoli, M, Musazzi, L, Barbon, A, Mingardi, Jessica, La Via, Luca, Tornese, Paolo, Carini, Giulia, Trontti, Kalevi, Seguini, Mara, Tardito, Daniela, Bono, Federica, Fiorentini, Chiara, Elia, Leonardo, Hovatta, Iiris, Popoli, Maurizio, Musazzi, Laura, Barbon, Alessandro, Mingardi, J, La Via, L, Tornese, P, Carini, G, Trontti, K, Seguini, M, Tardito, D, Bono, F, Fiorentini, C, Elia, L, Hovatta, I, Popoli, M, Musazzi, L, Barbon, A, Mingardi, Jessica, La Via, Luca, Tornese, Paolo, Carini, Giulia, Trontti, Kalevi, Seguini, Mara, Tardito, Daniela, Bono, Federica, Fiorentini, Chiara, Elia, Leonardo, Hovatta, Iiris, Popoli, Maurizio, Musazzi, Laura, and Barbon, Alessandro
- Abstract
Converging clinical and preclinical evidence demonstrates that depressive phenotypes are associated with synaptic dysfunction and dendritic simplification in cortico-limbic glutamatergic areas. On the other hand, the rapid antidepressant effect of acute ketamine is consistently reported to occur together with the rescue of dendritic atrophy and reduction of spine number induced by chronic stress in the hippocampus and prefrontal cortex of animal models of depression. Nevertheless, the molecular mechanisms underlying these morphological alterations remain largely unknown. Here, we found that miR-9-5p levels were selectively reduced in the hippocampus of rats vulnerable to Chronic Mild Stress (CMS), while acute subanesthetic ketamine restored its levels to basal condition in just 24h; miR-9-5p expression inversely correlated with the anhedonic phenotype. A decrease of miR-9-5p was reproduced in an in vitro model of stress, based on primary hippocampal neurons incubated with the stress hormone corticosterone. In both CMS animals and primary neurons, decreased miR-9-5p levels were associated with dendritic simplification, while treatment with ketamine completely rescued the changes. In vitro modulation of miR-9-5p expression showed a direct role of miR-9-5p in regulating dendritic length and spine density in mature primary hippocampal neurons. Among the putative target genes tested, Rest and Sirt1 were validated as biological targets in primary neuronal cultures. Moreover, in line with miR-9-5p changes, REST protein expression levels were remarkably increased in both CMS vulnerable animals and corticosterone-treated neurons, while ketamine completely abolished this alteration. Finally, the shortening of dendritic length in corticosterone-treated neurons was shown to be partly rescued by miR-9-5p overexpression and dependent on REST protein expression. Overall, our data unveiled the functional role of miR-9-5p in the remodeling of dendritic arbor induced by stress/cortic
- Published
- 2021
40. Dendritic remodeling of hippocampal pyramidal neurons, induced by chronic stress and fast-acting antidepressant ketamine, involves miR-9-5p
- Author
-
Mingardi, J, La Via, L, Tornese, P, Carini, G, Bono, F, Fiorentini, C, Popoli, M, Hovatta, I, Musazzi, L, Barbon, A, Jessica Mingardi, Luca La Via, Paolo Tornese, Giulia Carini, Federica Bono, Chiara Fiorentini, Maurizio Popoli, Iiris Hovatta, Laura Musazzi, Alessandro Barbon, Mingardi, J, La Via, L, Tornese, P, Carini, G, Bono, F, Fiorentini, C, Popoli, M, Hovatta, I, Musazzi, L, Barbon, A, Jessica Mingardi, Luca La Via, Paolo Tornese, Giulia Carini, Federica Bono, Chiara Fiorentini, Maurizio Popoli, Iiris Hovatta, Laura Musazzi, and Alessandro Barbon
- Published
- 2021
41. Cytopathology of Bronchoalveolar Lavages in COVID-19 Pneumonia: A Pilot Study
- Author
-
Canini, V, Bono, F, Calzavacca, P, Capitoli, G, Foti, G, Fraggetta, F, Galimberti, S, Gianatti, A, Giani, M, Nasr, A, Paciocco, G, Pagni, F, Rona, R, L'Imperio, V, Canini, Valentina, Bono, Francesca, Calzavacca, Paolo, Capitoli, Giulia, Foti, Giuseppe, Fraggetta, Filippo, Galimberti, Stefania, Gianatti, Andrea, Giani, Marco, Nasr, Ahmed, Paciocco, Giuseppe, Pagni, Fabio, Rona, Roberto, L'Imperio, Vincenzo, Canini, V, Bono, F, Calzavacca, P, Capitoli, G, Foti, G, Fraggetta, F, Galimberti, S, Gianatti, A, Giani, M, Nasr, A, Paciocco, G, Pagni, F, Rona, R, L'Imperio, V, Canini, Valentina, Bono, Francesca, Calzavacca, Paolo, Capitoli, Giulia, Foti, Giuseppe, Fraggetta, Filippo, Galimberti, Stefania, Gianatti, Andrea, Giani, Marco, Nasr, Ahmed, Paciocco, Giuseppe, Pagni, Fabio, Rona, Roberto, and L'Imperio, Vincenzo
- Abstract
BACKGROUND: Bronchoalveolar lavage (BAL) in patients with severe coronavirus disease 2019 (COVID-19) may provide additional and complementary findings for the management of these patients admitted to intensive care units (ICUs). This study addresses the cytological features of the infection and highlights the more influential inflammatory components. The correlation between pathological variables and clinical data is also analyzed. METHODS: The authors performed a retrospective analysis of the cytopathological features of BAL in 20 COVID-19 patients and 20 members of a matched cohort from a critical ICU who had acute respiratory distress syndrome caused by other pulmonary conditions. RESULTS: A comparison of the controls (n = 20) and the COVID-19 patients (n = 20) revealed that the latter had a higher neutrophil count (median, 63.8% of the cell count) with lower percentages of macrophages and lymphocytes. An increase in the expression of CD68-positive, monocytic multinucleated giant cells (MGCs) was reported; megakaryocytes were not detected on CD61 staining. Perls staining showed isolated elements. In situ RNA analysis demonstrated scattered chromogenic signals in type II pneumocytes. An ultrastructural analysis confirmed the presence of intracytoplasmic vacuoles containing rounded structures measuring 140 nm in diameter (putative viral particles). In COVID-19 patients, the clinicopathological correlation revealed a positive correlation between lactate dehydrogenase values and MGCs (r = 0.54). CONCLUSIONS: The analysis of BAL samples might be implemented as a routine practice for the evaluation of COVID-19 patients in ICUs in the appropriate clinical scenario. Additional studies using a larger sample size of patients who developed COVID-19 during the second wave of the epidemic in the autumn of 2020 are needed to further support our findings.
- Published
- 2021
42. PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
- Author
-
Crosta, S, Boldorini, R, Bono, F, Brambilla, V, Dainese, E, Fusco, N, Gianatti, A, L'Imperio, V, Morbini, P, Pagni, F, Crosta, Simona, Boldorini, Renzo, Bono, Francesca, Brambilla, Virginia, Dainese, Emanuele, Fusco, Nicola, Gianatti, Andrea, L'Imperio, Vincenzo, Morbini, Patrizia, Pagni, Fabio, Crosta, S, Boldorini, R, Bono, F, Brambilla, V, Dainese, E, Fusco, N, Gianatti, A, L'Imperio, V, Morbini, P, Pagni, F, Crosta, Simona, Boldorini, Renzo, Bono, Francesca, Brambilla, Virginia, Dainese, Emanuele, Fusco, Nicola, Gianatti, Andrea, L'Imperio, Vincenzo, Morbini, Patrizia, and Pagni, Fabio
- Abstract
Immune checkpoint inhibitors for blocking the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis are now available for squamous cell carcinoma of the head and neck (HNSCC) in relapsing and/or metastatic settings. In this work, we compared the resulting combined positive score (CPS) of PD-L1 using alternative methods adopted in routine clinical practice and determined the level of diagnostic agreement and inter-observer reliability in this setting. The study applied 5 different protocols on 40 tissue microarrays from HNSCC. The error rate of the individual protocols ranged from a minimum of 7% to a maximum of 21%, the sensitivity from 79% to 96%, and the specificity from 50% to 100%. In the intermediate group (1 ≤ CPS < 20), the majority of errors consisted of an underestimation of PD-L1 expression. In strong expressors, 5 out of 14 samples (36%) were correctly evaluated by all the protocols, but no protocol was able to correctly identify all the "strong expressors". The overall inter-observer agreement in PD-L1 CPS reached 87%. The inter-observer reliability was moderate, with an ICC of 0.774 (95% CI (0.651; 0.871)). In conclusion, our study showed moderate interobserver reliability among different protocols. In order to improve the performances, adequate specific training to evaluate PD-L1 by CPS in the HNSCC setting should be coordinated.
- Published
- 2021
43. Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site
- Author
-
Ercoli, T., Erro, R., Fabbrini, G., Pellicciari, R., Girlanda, P., Terranova, C., Avanzino, L., Di Biasio, F., Barone, P., Esposito, M., De Joanna, G., Eleopra, R., Bono, F., Manzo, L., Bentivoglio, Anna Rita, Petracca, Martina, Mascia, M. M., Albanese, A., Castagna, A., Ceravolo, R., Altavista, M. C., Scaglione, C., Magistrelli, L., Zibetti, M., Bertolasi, L., Coletti Moja, M., Cotelli, M. S., Cossu, G., Minafra, B., Pisani, A., Misceo, S., Modugno, N., Romano, M., Cassano, D., Berardelli, A., Defazio, G., Cimino, P., Scannapieco, S., Ferrazzano, G., Brigandi, A., Habetswallner, F., Pascarella, A., Ialongo, Tamara, Ramella, M., Mazzucchi, S., Moschella, V., Bentivoglio A. R. (ORCID:0000-0002-9663-095X), Petracca M., Ialongo T., Ercoli, T., Erro, R., Fabbrini, G., Pellicciari, R., Girlanda, P., Terranova, C., Avanzino, L., Di Biasio, F., Barone, P., Esposito, M., De Joanna, G., Eleopra, R., Bono, F., Manzo, L., Bentivoglio, Anna Rita, Petracca, Martina, Mascia, M. M., Albanese, A., Castagna, A., Ceravolo, R., Altavista, M. C., Scaglione, C., Magistrelli, L., Zibetti, M., Bertolasi, L., Coletti Moja, M., Cotelli, M. S., Cossu, G., Minafra, B., Pisani, A., Misceo, S., Modugno, N., Romano, M., Cassano, D., Berardelli, A., Defazio, G., Cimino, P., Scannapieco, S., Ferrazzano, G., Brigandi, A., Habetswallner, F., Pascarella, A., Ialongo, Tamara, Ramella, M., Mazzucchi, S., Moschella, V., Bentivoglio A. R. (ORCID:0000-0002-9663-095X), Petracca M., and Ialongo T.
- Abstract
Background: Adult-onset focal dystonia can spread to involve one, or less frequently, two additional body regions. Spread of focal dystonia to a third body site is not fully characterized. Materials and methods: We retrospectively analyzed data from the Italian Dystonia Registry, enrolling patients with segmental/multifocal dystonia involving at least two parts of the body or more. Survival analysis estimated the relationship between dystonia features and spread to a third body part. Results: We identified 340 patients with segmental/multifocal dystonia involving at least two body parts. Spread of dystonia to a third body site occurred in 42/241 patients (17.4%) with focal onset and 10/99 patients (10.1%) with segmental/multifocal dystonia at onset. The former had a greater tendency to spread than patients with segmental/multifocal dystonia at onset. Gender, years of schooling, comorbidity, family history of dystonia/tremor, age at dystonia onset, and disease duration could not predict spread to a third body site. Among patients with focal onset in different body parts (cranial, cervical, and upper limb regions), there was no association between site of focal dystonia onset and risk of spread to a third body site. Discussion and conclusion: Spread to a third body site occurs in a relative low percentage of patients with idiopathic adult-onset dystonia affecting two body parts. Regardless of the site of dystonia onset and of other demographic/clinical variables, focal onset seems to confer a greater risk of spread to a third body site in comparison to patients with segmental/multifocal dystonia at onset.
- Published
- 2021
44. Functional motor disorders associated with other neurological diseases: Beyond the boundaries of “organic” neurology
- Author
-
Tinazzi, M., Geroin, C., Erro, R., Marcuzzo, E., Cuoco, S., Ceravolo, R., Mazzucchi, S., Pilotto, A., Padovani, A., Romito, L. M., Eleopra, R., Zappia, M., Nicoletti, A., Dallocchio, C., Arbasino, C., Bono, F., Pascarella, A., Demartini, B., Gambini, O., Modugno, N., Olivola, E., Bonanni, L., Antelmi, E., Zanolin, E., Albanese, Alberto, Ferrazzano, G., de Micco, R., Lopiano, L., Calandra-Buonaura, G., Petracca, M., Esposito, M., Pisani, A., Manganotti, P., Stocchi, F., Coletti Moja, M., Antonini, A., Ercoli, T., Morgante, F., Albanese A. (ORCID:0000-0002-5864-0006), Tinazzi, M., Geroin, C., Erro, R., Marcuzzo, E., Cuoco, S., Ceravolo, R., Mazzucchi, S., Pilotto, A., Padovani, A., Romito, L. M., Eleopra, R., Zappia, M., Nicoletti, A., Dallocchio, C., Arbasino, C., Bono, F., Pascarella, A., Demartini, B., Gambini, O., Modugno, N., Olivola, E., Bonanni, L., Antelmi, E., Zanolin, E., Albanese, Alberto, Ferrazzano, G., de Micco, R., Lopiano, L., Calandra-Buonaura, G., Petracca, M., Esposito, M., Pisani, A., Manganotti, P., Stocchi, F., Coletti Moja, M., Antonini, A., Ercoli, T., Morgante, F., and Albanese A. (ORCID:0000-0002-5864-0006)
- Abstract
Background and purpose: The aims of this study were to describe the clinical manifestations of functional motor disorders (FMDs) coexisting with other neurological diseases (“comorbid FMDs”), and to compare comorbid FMDs with FMDs not overlapping with other neurological diseases (“pure FMDs”). Methods: For this multicenter observational study, we enrolled outpatients with a definite FMD diagnosis attending 25 tertiary movement disorder centers in Italy. Each patient with FMDs underwent a detailed clinical assessment including screening for other associated neurological conditions. Group comparisons (comorbid FMDs vs. pure FMDs) were performed in order to compare demographic and clinical variables. Logistic regression models were created to estimate the adjusted odds ratios (95% confidence intervals) of comorbid FMDs (dependent variable) in relation to sociodemographic and clinical characteristics (independent variables). Results: Out of 410 FMDs, 21.7% of patients (n = 89) had comorbid FMDs. The most frequent coexisting neurological diseases were migraine, cerebrovascular disease and parkinsonism. In the majority of cases (86.5%), FMDs appeared after the diagnosis of a neurological disease. Patients with comorbid FMDs were older, and more frequently had tremor, non-neurological comorbidities, paroxysmal non-epileptic seizures, major depressive disorders, and benzodiazepine intake. Multivariate regression analysis showed that diagnosis of comorbid FMDs was more likely associated with longer time lag until the final diagnosis of FMD, presence of tremor and non-neurological comorbidities. Conclusions: Our findings highlight the need for prompt diagnosis of FMDs, given the relatively high frequency of associated neurological and non-neurological diseases.
- Published
- 2021
45. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy
- Author
-
SAVI, P., HERAULT, J.P., DUCHAUSSOY, P., MILLET, L., SCHAEFFER, P., PETITOU, M., BONO, F., and HERBERT, J.M.
- Published
- 2008
- Full Text
- View/download PDF
46. Use of a portable VIS NIR device to predict table olives quality
- Author
-
Vallone M., Alleri M., Bono F., Catania P., Vallone M., Alleri M., Bono F., and Catania P.
- Subjects
damage, fruit, firmness, postharvest ,Settore AGR/09 - Meccanica Agraria - Abstract
There is a growing interest today in high-quality and sustainable production especially in the agro-food sector where the use of automated, precise and non-destructive monitoring analytical systems is spreading more and more. In table olives consumption colour and texture are very important quality attributes deriving from ripening, size of the cell wall, middle lamella and fibrous tissues that can be compromised by bruising during harvest operations or postharvest handling. Mechanical damage also accelerates physiological processes, which lead to senescence, spoilage and loss of nutritional value. Nocellara del Belice cultivar is one of the most important table olive varieties in Italy both for the production and the marketed quantities, with an average annual production of 25,000 t. The aim of this study was to evaluate the feasibility of applying vis NIR spectroscopy as a non-destructive technique on Nocellara del Belice table olives to predict colour and firmness during harvest and post-harvest operations. The spectral acquisitions were performed using a portable vis NIR device (600 - 1000 nm). A regression model was considered to evaluate the prediction capacity of vis NIR starting from the observed values of a validation data set. The system gave excellent performance in predicting table olives colour (R2 = 0.96 for “hue”), while the results showed a very low vis NIR ability to predict Nocellara del Belice table olives firmness (R2 = 0.18) which make this device unsuitable for the purpose. The possibility of applying vis NIR spectroscopy in field before harvest or for selection in postharvest operations is very encouraging for colour prediction and seems to be not adequate for firmness or damage evaluation.
- Published
- 2019
47. Bilateral transverse sinus stenosis and idiopathic intracranial hypertension without papilledema in chronic tension-type headache
- Author
-
Bono, F., Messina, D., Giliberto, C., Cristiano, D., Broussard, G., D’Asero, S., Condino, F., Mangone, L., Mastrandrea, C., Fera, F., and Quattrone, A.
- Published
- 2008
- Full Text
- View/download PDF
48. Molecular trait of follicular-patterned thyroid neoplasms defined by MALDI-imaging
- Author
-
Piga, I, Capitoli, G, Clerici, F, Brambilla, V, Leni, D, Scardilli, M, Canini, V, Cipriani, N, Bono, F, Valsecchi, M, Galimberti, S, Magni, F, Pagni, F, Piga, Isabella, Capitoli, Giulia, Clerici, Francesca, Brambilla, Virginia, Leni, Davide, Scardilli, Marcella, Canini, Valentina, Cipriani, Nicole, Bono, Francesca, Valsecchi, Maria Grazia, Galimberti, Stefania, Magni, Fulvio, Pagni, Fabio, Piga, I, Capitoli, G, Clerici, F, Brambilla, V, Leni, D, Scardilli, M, Canini, V, Cipriani, N, Bono, F, Valsecchi, M, Galimberti, S, Magni, F, Pagni, F, Piga, Isabella, Capitoli, Giulia, Clerici, Francesca, Brambilla, Virginia, Leni, Davide, Scardilli, Marcella, Canini, Valentina, Cipriani, Nicole, Bono, Francesca, Valsecchi, Maria Grazia, Galimberti, Stefania, Magni, Fulvio, and Pagni, Fabio
- Abstract
In the field of thyroid neoplasms, the most interesting recent change regards the introduction of a new terminology for follicular-patterned thyroid tumors, named Noninvasive Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP). This pre-malignant tumor is considered to be the putative precursor of invasive carcinomas. However, given that several issues are still unresolved, the application of ancillary tools, based on omics-techniques, may improve the clinical management of these challenging cases. The present paper highlights the proteomic profiles of a series of NIFTPs submitted to Fine Needle Aspirations (FNAs) and analysed by MALDI-imaging in order to confirm the heterogeneous phenotype of nodules included in the present NIFTP terminology and to underline the necessity of more accurate biomarkers that can be used for their characterization. Ethical and economic implications in terms of healthcare costs, operative risks, morbidity, as well as the potential need for lifelong hormone replacement therapy, seem to be significant reasons to approach the characterization of NIFTPs using alternative tools such as MALDI-MSI.
- Published
- 2020
49. Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study
- Author
-
Tinazzi, M., Morgante, F., Marcuzzo, E., Erro, R., Barone, P., Ceravolo, R., Mazzucchi, S., Pilotto, A., Padovani, A., Romito, L. M., Eleopra, R., Zappia, M., Nicoletti, A., Dallocchio, C., Arbasino, C., Bono, F., Pascarella, A., Demartini, B., Gambini, O., Modugno, N., Olivola, E., Di Stefano, V., Albanese, A., Ferrazzano, G., Tessitore, A., Zibetti, M., Calandra-Buonaura, G., Petracca, M., Esposito, M., Pisani, A., Manganotti, P., Stocchi, F., Coletti Moja, M., Antonini, A., Defazio, G., Geroin, C., Albanese A. (ORCID:0000-0002-5864-0006), Petracca M., Tinazzi, M., Morgante, F., Marcuzzo, E., Erro, R., Barone, P., Ceravolo, R., Mazzucchi, S., Pilotto, A., Padovani, A., Romito, L. M., Eleopra, R., Zappia, M., Nicoletti, A., Dallocchio, C., Arbasino, C., Bono, F., Pascarella, A., Demartini, B., Gambini, O., Modugno, N., Olivola, E., Di Stefano, V., Albanese, A., Ferrazzano, G., Tessitore, A., Zibetti, M., Calandra-Buonaura, G., Petracca, M., Esposito, M., Pisani, A., Manganotti, P., Stocchi, F., Coletti Moja, M., Antonini, A., Defazio, G., Geroin, C., Albanese A. (ORCID:0000-0002-5864-0006), and Petracca M.
- Abstract
Background: Functional motor disorders (FMDs) are abnormal movements that are significantly altered by distractive maneuvers and are incongruent with movement disorders seen in typical neurological diseases. Objective: The objectives of this article are to (1) describe the clinical manifestations of FMDs, including nonmotor symptoms and occurrence of other functional neurological disorders (FND); and (2) to report the frequency of isolated and combined FMDs and their relationship with demographic and clinical variables. Methods: For this multicenter, observational study, we enrolled consecutive outpatients with a definite diagnosis of FMDs attending 25 tertiary movement disorders centers in Italy. Each patient underwent a detailed clinical evaluation with a definition of the phenotype and number of FMDs (isolated, combined) and an assessment of associated neurological and psychiatric symptoms. Results: Of 410 FMDs (71% females; mean age, 47 ± 16.1 years) the most common phenotypes were weakness and tremor. People with FMDs had higher educational levels than the general population and frequent nonmotor symptoms, especially anxiety, fatigue, and pain. Almost half of the patients with FMDs had other FNDs, such as sensory symptoms, nonepileptic seizures, and visual symptoms. Patients with combined FMDs showed a higher burden of nonmotor symptoms and more frequent FNDs. Multivariate regression analysis showed that a diagnosis of combined FMDs was more likely to be delivered by a movement disorders neurologist. Also, FMD duration, pain, insomnia, diagnosis of somatoform disease, and treatment with antipsychotics were all significantly associated with combined FMDs. Conclusions: Our findings highlight the need for multidimensional assessments in patients with FMDs given the high frequency of nonmotor symptoms and other FNDs, especially in patients with combined FMDs.
- Published
- 2020
50. Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?
- Author
-
Defazio, G., Fabbrini, G., Erro, R., Albanese, Alberto, Barone, P., Zibetti, M., Esposito, M., Pellicciari, R., Avanzino, L., Bono, F., Eleopra, R., Bertolasi, L., Altavista, M. C., Cotelli, M. S., Ceravolo, R., Scaglione, C., Bentivoglio, Anna Rita, Cossu, G., Coletti Moja, M., Girlanda, P., Misceo, S., Pisani, A., Mascia, M. M., Ercoli, T., Tinazzi, M., Maderna, L., Minafra, B., Magistrelli, L., Romano, M., Aguggia, M., Tambasco, N., Castagna, A., Cassano, D., Berardelli, A., Ferrazzano, G., Lalli, S., Silvestre, F., Manganelli, F., Di Biasio, F., Marchese, R., Demonte, G., Santangelo, D., Devigili, G., Durastanti, V., Turla, M., Mazzucchi, S., Petracca, Martina, Oppo, V., Barbero, P., Morgante, F., Di Lazzaro, G., Squintani, G., Modugno, N., Albanese A. (ORCID:0000-0002-5864-0006), Bentivoglio A. R. (ORCID:0000-0002-9663-095X), Petracca M., Defazio, G., Fabbrini, G., Erro, R., Albanese, Alberto, Barone, P., Zibetti, M., Esposito, M., Pellicciari, R., Avanzino, L., Bono, F., Eleopra, R., Bertolasi, L., Altavista, M. C., Cotelli, M. S., Ceravolo, R., Scaglione, C., Bentivoglio, Anna Rita, Cossu, G., Coletti Moja, M., Girlanda, P., Misceo, S., Pisani, A., Mascia, M. M., Ercoli, T., Tinazzi, M., Maderna, L., Minafra, B., Magistrelli, L., Romano, M., Aguggia, M., Tambasco, N., Castagna, A., Cassano, D., Berardelli, A., Ferrazzano, G., Lalli, S., Silvestre, F., Manganelli, F., Di Biasio, F., Marchese, R., Demonte, G., Santangelo, D., Devigili, G., Durastanti, V., Turla, M., Mazzucchi, S., Petracca, Martina, Oppo, V., Barbero, P., Morgante, F., Di Lazzaro, G., Squintani, G., Modugno, N., Albanese A. (ORCID:0000-0002-5864-0006), Bentivoglio A. R. (ORCID:0000-0002-9663-095X), and Petracca M.
- Abstract
Background: Acute peripheral trauma is a controversial risk factor for idiopathic dystonia. Materials and methods: We retrospectively analyzed data from the Italian Dystonia Registry regarding the occurrence of acute peripheral trauma severe enough to require medical attention in 1382 patients with adult-onset idiopathic dystonia and 200 patients with acquired adult-onset dystonia. Results: Patients with idiopathic and acquired dystonia showed a similar burden of peripheral trauma in terms of the number of patients who experienced trauma (115/1382 vs. 12/200, p = 0.3) and the overall number of injuries (145 for the 1382 idiopathic patients and 14 for the 200 patients with secondary dystonia, p = 0.2). Most traumas occurred before the onset of idiopathic or secondary dystonia but only a minority of such injuries (14 in the idiopathic group, 2 in the acquired group, p = 0.6) affected the same body part as that affected by dystonia. In the idiopathic group, the elapsed time between trauma and dystonia onset was 8.1 ± 9.2 years; only six of the 145 traumas (4.1%) experienced by 5/1382 idiopathic patients (0.36%) occurred one year or less before dystonia onset; in the acquired dystonia group, the two patients experienced prior trauma to the dystonic body part 5 and 6 years before dystonia development. Discussion and conclusion: Our data suggest that the contribution of peripheral acute trauma to idiopathic dystonia is negligible, if anything, and likely involves only a small subset of patients.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.